Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Sofosbuvir | 5 | 2021 | 518 | 2.20 | Why? |
| Egypt | 19 | 2021 | 1211 | 1.86 | Why? |
| Liver Cirrhosis | 12 | 2020 | 1810 | 1.83 | Why? |
| Hepatitis C, Chronic | 7 | 2020 | 973 | 1.78 | Why? |
| Hepacivirus | 8 | 2020 | 1509 | 1.57 | Why? |
| Interleukin-12 Subunit p40 | 2 | 2019 | 26 | 1.50 | Why? |
| Hepatitis C | 6 | 2020 | 1514 | 1.40 | Why? |
| Ribavirin | 3 | 2019 | 1182 | 1.25 | Why? |
| Esophageal and Gastric Varices | 5 | 2020 | 117 | 1.17 | Why? |
| Gastrointestinal Hemorrhage | 4 | 2020 | 669 | 1.07 | Why? |
| Carcinoma, Hepatocellular | 3 | 2018 | 1222 | 1.02 | Why? |
| Thiazoles | 2 | 2019 | 496 | 1.00 | Why? |
| Sclerotherapy | 2 | 2019 | 23 | 0.95 | Why? |
| Liver Neoplasms | 3 | 2018 | 1666 | 0.89 | Why? |
| Non-alcoholic Fatty Liver Disease | 3 | 2019 | 907 | 0.82 | Why? |
| Muscle Cramp | 1 | 2019 | 1 | 0.81 | Why? |
| Methocarbamol | 1 | 2019 | 4 | 0.81 | Why? |
| Simeprevir | 1 | 2020 | 62 | 0.81 | Why? |
| Lactulose | 1 | 2019 | 9 | 0.80 | Why? |
| Sclerosing Solutions | 1 | 2019 | 4 | 0.80 | Why? |
| Enbucrilate | 1 | 2019 | 7 | 0.79 | Why? |
| Interferon-alpha | 2 | 2019 | 1442 | 0.78 | Why? |
| HSP47 Heat-Shock Proteins | 1 | 2018 | 2 | 0.78 | Why? |
| Muscle Relaxants, Central | 1 | 2019 | 48 | 0.77 | Why? |
| Hemostatic Techniques | 1 | 2019 | 60 | 0.75 | Why? |
| Genetic Association Studies | 2 | 2019 | 559 | 0.74 | Why? |
| Receptors, Calcitriol | 1 | 2019 | 102 | 0.73 | Why? |
| Pregabalin | 1 | 2018 | 22 | 0.72 | Why? |
| Helicobacter Infections | 2 | 2019 | 216 | 0.70 | Why? |
| Genotype | 6 | 2020 | 4697 | 0.69 | Why? |
| Helicobacter pylori | 2 | 2019 | 262 | 0.68 | Why? |
| Sustained Virologic Response | 4 | 2020 | 378 | 0.67 | Why? |
| Blood Cells | 1 | 2017 | 104 | 0.66 | Why? |
| Polyethylene Glycols | 2 | 2019 | 574 | 0.65 | Why? |
| Lactoferrin | 1 | 2018 | 208 | 0.63 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2020 | 451 | 0.60 | Why? |
| Liver | 3 | 2020 | 4007 | 0.60 | Why? |
| Liver Diseases | 3 | 2021 | 2698 | 0.59 | Why? |
| Antiviral Agents | 11 | 2021 | 41703 | 0.57 | Why? |
| Gastrointestinal Agents | 1 | 2019 | 393 | 0.55 | Why? |
| Lipid Metabolism | 1 | 2019 | 572 | 0.53 | Why? |
| Myeloid-Derived Suppressor Cells | 1 | 2017 | 316 | 0.53 | Why? |
| Genetic Predisposition to Disease | 2 | 2019 | 4027 | 0.53 | Why? |
| Pain, Postoperative | 1 | 2018 | 289 | 0.53 | Why? |
| Fibrosis | 1 | 2017 | 800 | 0.53 | Why? |
| Analgesics | 1 | 2018 | 451 | 0.51 | Why? |
| Neoplasm Proteins | 1 | 2019 | 501 | 0.51 | Why? |
| Drug Therapy, Combination | 8 | 2021 | 7268 | 0.50 | Why? |
| Proton Pump Inhibitors | 1 | 2017 | 377 | 0.47 | Why? |
| Pancreatic Neoplasms | 1 | 2019 | 609 | 0.45 | Why? |
| Ivermectin | 1 | 2021 | 973 | 0.45 | Why? |
| Polymorphism, Genetic | 1 | 2018 | 1074 | 0.41 | Why? |
| Chloroquine | 3 | 2021 | 3152 | 0.39 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2019 | 3607 | 0.37 | Why? |
| Hydroxychloroquine | 3 | 2021 | 12447 | 0.36 | Why? |
| Academic Medical Centers | 1 | 2021 | 3088 | 0.36 | Why? |
| alpha-Fetoproteins | 2 | 2019 | 72 | 0.36 | Why? |
| Ascitic Fluid | 2 | 2020 | 169 | 0.33 | Why? |
| Acute-On-Chronic Liver Failure | 2 | 2020 | 237 | 0.33 | Why? |
| Health Resources | 1 | 2021 | 2592 | 0.33 | Why? |
| Nitro Compounds | 2 | 2019 | 190 | 0.33 | Why? |
| Patient Care Team | 1 | 2021 | 3556 | 0.31 | Why? |
| Developing Countries | 2 | 2021 | 4283 | 0.30 | Why? |
| Anti-Infective Agents | 1 | 2017 | 1766 | 0.29 | Why? |
| Treatment Outcome | 11 | 2021 | 51732 | 0.27 | Why? |
| Middle Aged | 26 | 2021 | 270681 | 0.25 | Why? |
| Drug Administration Schedule | 2 | 2020 | 2324 | 0.24 | Why? |
| Disease Management | 1 | 2021 | 6841 | 0.24 | Why? |
| Female | 32 | 2021 | 380317 | 0.24 | Why? |
| Male | 29 | 2021 | 367725 | 0.23 | Why? |
| Brain Ischemia | 1 | 2017 | 2813 | 0.23 | Why? |
| Humans | 47 | 2021 | 930598 | 0.22 | Why? |
| Recurrence | 4 | 2019 | 3675 | 0.22 | Why? |
| Adult | 22 | 2021 | 244371 | 0.21 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2019 | 6166 | 0.21 | Why? |
| Hypertension, Portal | 2 | 2020 | 73 | 0.21 | Why? |
| Liver Circulation | 1 | 2020 | 12 | 0.21 | Why? |
| Renal Dialysis | 1 | 2017 | 4358 | 0.21 | Why? |
| Blood Glucose | 3 | 2019 | 3642 | 0.20 | Why? |
| Valine | 1 | 2021 | 359 | 0.19 | Why? |
| Thioacetamide | 1 | 2018 | 5 | 0.19 | Why? |
| Insulin | 2 | 2019 | 1316 | 0.19 | Why? |
| Facility Design and Construction | 1 | 2020 | 189 | 0.19 | Why? |
| Hepatic Stellate Cells | 1 | 2018 | 35 | 0.19 | Why? |
| Silymarin | 1 | 2018 | 17 | 0.19 | Why? |
| Endoscopy, Gastrointestinal | 2 | 2020 | 1545 | 0.18 | Why? |
| Hepatic Encephalopathy | 1 | 2019 | 88 | 0.18 | Why? |
| Hemostasis, Endoscopic | 1 | 2018 | 24 | 0.18 | Why? |
| Tumor Escape | 1 | 2017 | 36 | 0.18 | Why? |
| Matrix Metalloproteinase 2 | 1 | 2018 | 85 | 0.18 | Why? |
| Blood Circulation | 1 | 2017 | 99 | 0.18 | Why? |
| Cephalosporins | 1 | 2020 | 250 | 0.18 | Why? |
| Serum Amyloid A Protein | 1 | 2020 | 211 | 0.18 | Why? |
| Salmonella Infections | 1 | 2019 | 82 | 0.18 | Why? |
| Acetaminophen | 1 | 2020 | 326 | 0.17 | Why? |
| Carbamates | 1 | 2021 | 485 | 0.17 | Why? |
| Peritonitis | 1 | 2020 | 217 | 0.17 | Why? |
| Pyrrolidines | 1 | 2021 | 558 | 0.17 | Why? |
| Transforming Growth Factor beta1 | 1 | 2018 | 204 | 0.16 | Why? |
| Oseltamivir | 1 | 2020 | 583 | 0.16 | Why? |
| Prospective Studies | 7 | 2021 | 43301 | 0.15 | Why? |
| Chemoprevention | 1 | 2021 | 585 | 0.15 | Why? |
| Portal Vein | 1 | 2018 | 193 | 0.15 | Why? |
| Bacterial Infections | 2 | 2020 | 2229 | 0.15 | Why? |
| Blood Proteins | 1 | 2020 | 551 | 0.15 | Why? |
| Imidazoles | 1 | 2021 | 631 | 0.15 | Why? |
| Carcinogenesis | 1 | 2017 | 236 | 0.15 | Why? |
| Analgesia | 1 | 2018 | 211 | 0.14 | Why? |
| Hospitals, University | 2 | 2018 | 4173 | 0.14 | Why? |
| Pre-Eclampsia | 1 | 2021 | 599 | 0.14 | Why? |
| Fatty Liver | 1 | 2019 | 299 | 0.14 | Why? |
| Rivaroxaban | 1 | 2018 | 467 | 0.14 | Why? |
| Warfarin | 1 | 2018 | 402 | 0.13 | Why? |
| Hospital Mortality | 1 | 2018 | 22087 | 0.13 | Why? |
| Stroke | 1 | 2017 | 8839 | 0.13 | Why? |
| RNA, Viral | 5 | 2020 | 32276 | 0.13 | Why? |
| Hemodynamics | 2 | 2020 | 1562 | 0.13 | Why? |
| Factor Xa Inhibitors | 1 | 2018 | 490 | 0.13 | Why? |
| Zinc | 1 | 2020 | 817 | 0.12 | Why? |
| Fibrinogen | 1 | 2019 | 1048 | 0.12 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.12 | Why? |
| Polymerase Chain Reaction | 2 | 2019 | 6740 | 0.12 | Why? |
| Aged | 9 | 2021 | 215776 | 0.12 | Why? |
| Insulin Resistance | 1 | 2018 | 669 | 0.12 | Why? |
| Waiting Lists | 1 | 2020 | 1388 | 0.12 | Why? |
| Personnel Staffing and Scheduling | 1 | 2020 | 1578 | 0.11 | Why? |
| Pain | 1 | 2019 | 1084 | 0.11 | Why? |
| Shock, Septic | 1 | 2021 | 1313 | 0.11 | Why? |
| Up-Regulation | 1 | 2019 | 2249 | 0.11 | Why? |
| Rats | 1 | 2018 | 2764 | 0.10 | Why? |
| Hydrocortisone | 1 | 2020 | 1790 | 0.10 | Why? |
| Pregnancy Complications | 1 | 2021 | 1388 | 0.10 | Why? |
| Pyrazines | 1 | 2021 | 1783 | 0.10 | Why? |
| Physician's Role | 1 | 2019 | 853 | 0.10 | Why? |
| Gastroenterology | 1 | 2020 | 1352 | 0.10 | Why? |
| Amides | 1 | 2021 | 1864 | 0.10 | Why? |
| Risk Factors | 7 | 2021 | 71621 | 0.10 | Why? |
| Length of Stay | 3 | 2021 | 11042 | 0.09 | Why? |
| Antioxidants | 1 | 2018 | 1593 | 0.09 | Why? |
| Recombinant Proteins | 1 | 2019 | 3786 | 0.09 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.09 | Why? |
| Preoperative Care | 1 | 2018 | 1515 | 0.09 | Why? |
| Double-Blind Method | 1 | 2019 | 5988 | 0.09 | Why? |
| Interferon-gamma | 1 | 2017 | 2711 | 0.08 | Why? |
| Respiration, Artificial | 3 | 2021 | 22116 | 0.08 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.08 | Why? |
| Young Adult | 5 | 2020 | 93724 | 0.07 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.07 | Why? |
| Kidney | 1 | 2020 | 3648 | 0.07 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2021 | 10649 | 0.07 | Why? |
| Pregnancy Complications, Infectious | 2 | 2021 | 11559 | 0.07 | Why? |
| Pediatrics | 1 | 2021 | 2969 | 0.07 | Why? |
| Blood Coagulation | 1 | 2018 | 2768 | 0.07 | Why? |
| Adolescent | 4 | 2020 | 86841 | 0.07 | Why? |
| Ultrasonography | 1 | 2021 | 4409 | 0.07 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.07 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.07 | Why? |
| Liver Function Tests | 2 | 2020 | 1325 | 0.07 | Why? |
| Vitamin D | 1 | 2019 | 2904 | 0.06 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.06 | Why? |
| Feces | 1 | 2017 | 4235 | 0.06 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.06 | Why? |
| Venous Thrombosis | 1 | 2018 | 2739 | 0.06 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.06 | Why? |
| Biomarkers | 3 | 2020 | 23361 | 0.06 | Why? |
| Splenic Vein | 1 | 2020 | 9 | 0.05 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 6653 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.05 | Why? |
| Prognosis | 3 | 2020 | 32490 | 0.05 | Why? |
| Combined Modality Therapy | 2 | 2021 | 3395 | 0.05 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.05 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.05 | Why? |
| Hypertension, Pregnancy-Induced | 1 | 2021 | 208 | 0.05 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.05 | Why? |
| Cross-Sectional Studies | 4 | 2021 | 53120 | 0.05 | Why? |
| Phlebography | 1 | 2018 | 65 | 0.05 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.05 | Why? |
| Virus Replication | 1 | 2020 | 14331 | 0.04 | Why? |
| Ultrasonography, Doppler, Color | 1 | 2018 | 107 | 0.04 | Why? |
| Gastric Antral Vascular Ectasia | 1 | 2017 | 3 | 0.04 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.04 | Why? |
| Ligation | 1 | 2017 | 84 | 0.04 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.04 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.04 | Why? |
| Anticoagulants | 1 | 2018 | 9563 | 0.04 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.04 | Why? |
| Reference Standards | 1 | 2020 | 1163 | 0.04 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Morbidity | 1 | 2021 | 1426 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.04 | Why? |
| Pregnancy | 3 | 2021 | 23879 | 0.03 | Why? |
| Survival Rate | 2 | 2021 | 9206 | 0.03 | Why? |
| Patient Participation | 1 | 2021 | 829 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Asia | 1 | 2020 | 2399 | 0.03 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.03 | Why? |
| Fasting | 1 | 2018 | 555 | 0.03 | Why? |
| Fever | 2 | 2021 | 7795 | 0.03 | Why? |
| Disease Progression | 2 | 2020 | 13580 | 0.03 | Why? |
| Premature Birth | 1 | 2021 | 2151 | 0.02 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.02 | Why? |
| Animals | 1 | 2018 | 78931 | 0.02 | Why? |
| Computed Tomography Angiography | 1 | 2018 | 2153 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2021 | 3803 | 0.02 | Why? |
| International Cooperation | 1 | 2021 | 3436 | 0.02 | Why? |
| Global Health | 2 | 2021 | 13911 | 0.02 | Why? |
| Cough | 1 | 2021 | 4891 | 0.02 | Why? |
| Risk | 1 | 2019 | 5288 | 0.02 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.02 | Why? |
| Hypoglycemic Agents | 1 | 2019 | 2165 | 0.02 | Why? |
| Hemorrhage | 1 | 2018 | 3013 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2021 | 17020 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.01 | Why? |
| Child | 2 | 2021 | 70012 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Registries | 1 | 2020 | 12327 | 0.01 | Why? |
| United Kingdom | 1 | 2020 | 18046 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.01 | Why? |
| Incidence | 1 | 2019 | 25622 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2019 | 8207 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.01 | Why? |
| Lung | 1 | 2021 | 31049 | 0.01 | Why? |
Abd-Elsalam's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(231)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(350)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_